Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.

@article{Zeng2015EfficacyAS,
  title={Efficacy and safety of linagliptin as monotherapy or add-on treatment in Asian patients with suboptimal glycemic control: a pooled analysis.},
  author={Z. P. Zeng and Dong Seop Choi and Viswanathan Mohan and Angela Emser and Kamran Siddiqui and Yan Gong and Sanjay R. Patel and Hans J Woerle},
  journal={Current medical research and opinion},
  year={2015},
  volume={31 1},
  pages={99-106}
}
AIMS To evaluate the efficacy and safety of the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin in Asian patients with type 2 diabetes mellitus (T2DM), a rapidly increasing population. METHODS Data were pooled for Asian patients receiving linagliptin orally once daily, as monotherapy or added to existing oral antidiabetes therapies, in multinational… CONTINUE READING